Impact of metformin versus repaglinide on postprandial glycaemia and plasma lipoproteins in non-obese patients with type-2 diabetes mellitus (T2DM)

被引：0
|
作者：
Lund, S. S. [1 ]
Tarnow, L. [1 ]
Smidt, U. M. [1 ]
Frandsen, M. [1 ]
Pedersen, O. [1 ]
Parving, H-H. [1 ]
Vaag, A. A. [1 ]
机构：
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2007年 / 8卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(07)71734-8
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：193 / 193
页数：1
相关论文
共 50 条
  • [1] Effect of metformin vs repaglinide on postprandial glycaemia, plasma lipoproteins and free fatty acids in non-obese patients with type-2 diabetes (T2DM)
    Lund, SS
    Tarnow, L
    Poulsen, G
    Frandsen, M
    Smidt, U
    Pedersen, O
    Parving, HH
    Vaag, A
    DIABETOLOGIA, 2005, 48 : A285 - A285
  • [2] Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
    Lund, Soren S.
    Tarnow, Lise
    Frandsen, Merete
    Smidt, Ulla M.
    Pedersen, Oluf
    Parving, Hans-Henrik
    Vaag, Allan A.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (01) : 35 - 46
  • [3] Impact of metformin versus repaglinide on glycemic regulation and non-glycemic cardiovascular risk-markers in non-obese patients with type-2 diabetes
    Lund, S.
    Tarnow, L.
    Poulsen, G.
    Stehouwer, C.
    Schalkwijk, C.
    Gram, J.
    Smidt, U.
    Pedersen, O.
    Parving, H. -H.
    Vaag, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 159 - 159
  • [4] Effect of metformin vs. repaglinide on glycemic control and non-glycerine cardiovascular risk-factors in non-obese patients with type-2 diabetes mellitus (T2DM) uncontrolled by diet (The ReMet-Study)
    Lund, S
    Tarnow, L
    Frandsen, M
    Pedersen, O
    Parving, HH
    Vaag, A
    DIABETES, 2003, 52 : A451 - A451
  • [5] Efficacy of low dose sibutramine in obese type-2 diabetes mellitus (T2DM) Indian patients
    Gupta, Ashwani K.
    Badyal, Dinesh K.
    Matreja, Prithpal S.
    Khosla, Prem P.
    John, Mary
    WORLD FAMILY MEDICINE, 2012, 10 (03): : 29 - 35
  • [6] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Christophe Bardin
    Estelle Nobecourt
    Etienne Larger
    François Chast
    Jean-Marc Treluyer
    Saik Urien
    European Journal of Clinical Pharmacology, 2012, 68 : 961 - 968
  • [7] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Bardin, Christophe
    Nobecourt, Estelle
    Larger, Etienne
    Chast, Francois
    Treluyer, Jean-Marc
    Urien, Saik
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (06) : 961 - 968
  • [8] Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients
    Kosmalski, M.
    Drozdowska, A.
    Sliwinska, A.
    Drzewoski, J.
    ADVANCES IN MEDICAL SCIENCES, 2012, 57 (01): : 65 - 70
  • [9] Renal outcomes in metformin users versus non-metformin users in veterans with type 2 diabetes mellitus (T2DM).
    Gosmanova, E.
    Canada, R. B.
    Mangold, T. A.
    Rawls, W. N.
    Wall, B. M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A42 - A42
  • [10] Effect of metformin vs. repaglinide on glycaemic control and non-glycaemic cardiovascular risk-factors in non-obese patients with Type 2 diabetes mellitus (T2DM) uncontrolled by diet (The ReMet-study)
    Lund, SS
    Tarnow, L
    Poulsen, G
    Frandsen, M
    Smith, UM
    Pedersen, O
    Parving, HH
    Vaag, A
    DIABETOLOGIA, 2004, 47 : A252 - A252
12345